Guidelines for Genetic Testing and Management of Alport Syndrome.
Judy SavigeBeata Stefania Lipska-ZiętkiewiczElizabeth WatsonJens Michael HertzConstantinos DeltasFrancesca MariPascale HilbertPavlina PlevovaPeter ByersAgne CerkauskaiteMartin GregoryRimante CerkauskieneDanica Galesic LjubanovicFrancesca BecherucciCarmela ErrichielloLaura MassellaValeria AielloRachel LennonLouise HopkinsonAnia KoziellAdrian LunguHansjorg Martin RotheJulia HoefeleMiriam ZacchiaTamara Nikuseva MarticAsheeta GuptaAlbertien van EerdeSusie GearSamuela LandiniViviana PalazzoLaith Al-RabadiKathleen ClaesAnniek CorveleynEvelien Van HoofMicheel van GeelMaggie WilliamsEmma AshtonHendica BelgeElisabet ArsAgnieszka BierzynskaConcetta GangemiAlessandra RenieriHelen StoreyFrances FlinterPublished in: Clinical journal of the American Society of Nephrology : CJASN (2021)
Genetic testing for pathogenic COL4A3-5 variants is usually undertaken to investigate the cause of persistent hematuria, especially with a family history of hematuria or kidney function impairment. Alport syndrome experts now advocate genetic testing for persistent hematuria, even when a heterozygous pathogenic COL4A3 or COL4A4 is suspected, and cascade testing of their first-degree family members because of their risk of impaired kidney function. The experts recommend too that COL4A3 or COL4A4 heterozygotes do not act as kidney donors. Testing for variants in the COL4A3-COL4A5 genes should also be performed for persistent proteinuria and steroid-resistant nephrotic syndrome due to suspected inherited FSGS and for familial IgA glomerulonephritis and kidney failure of unknown cause.